Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group.
-
Authors
-
-
Hallinan, Christine Mary1, 2
-
Eden, Edward3
-
Graham, Myfanwy3, 4
-
Greenwood, Lisa-Marie5
-
Mills, Jessica6
-
Popat, Amirali7
-
Truong, Linda3, 8, 9
-
Bonomo, Yvonne1, 10
-
1
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia.
,
(Australia)
-
2
Department of General Practice, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia.
,
(Australia)
-
3
School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia.
,
(Australia)
-
4
Hunter Medical Research Institute, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia.
,
(Australia)
-
5
School of Psychology, Australian National University, Canberra, ACT, Australia.
,
(Australia)
-
6
School of Psychology, Illawarra Health and Medical Research Institute (IHMRI), Faculty of the Arts Social Sciences and Humanities, University of Wollongong, Wollongong, NSW, Australia.
,
(Australia)
-
7
School of Pharmacy, Faculty of Health and Behavioural Sciences, The University of Queensland, Woolloongabba, QLD, Australia.
,
(Australia)
-
8
Department of Neurology, Sydney Children's Hospital Randwick, Sydney, NSW, Australia.
,
(Australia)
-
9
School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
,
(Australia)
-
10
Department of Addiction Medicine, St Vincent's Hospital Melbourne, VIC, Australia.
,
(Australia)
- Type
- Published Article
- Journal
-
Journal of psychopharmacology (Oxford, England)
- Publication Date
-
Jun 01, 2022
- Volume
-
36
- Issue
-
6
- Pages
-
661–665
- Identifiers
-
DOI: 10.1177/02698811211035394
-
PMID: 34344208
- Source
-
Medline
- Keywords
-
- Language
-
English
- License
-
Unknown
Abstract
Amidst growing global acceptance of medicinal cannabinoids as a potential therapeutic interest in cannabidiol (CBD) is increasing. In Australia in 2020, a government inquiry examined the barriers that the public are experiencing in accessing medicinal cannabis. A number of recommendations to improve access were made. In response to these recommendations, the Australian therapeutics regulatory authority down-scheduled CBD from Prescription Only (Schedule 4) to Pharmacist Only (Schedule 3). As a group of early to mid-career researchers of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), we propose some considerations in relation to over-the-counter availability of CBD and opportunities to improve knowledge about its potential therapeutic benefits alongside its increased uptake.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/16/2022 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/34344208
